Navigation Links
Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
Date:9/28/2010

BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to increasing generic availability of antihypertensive agents, the hypertension drug market will decline from $26 billion in 2009 to $23 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Hypertension reveal that the market-leading drug, Novartis's Diovan/Tareg, will suffer the greatest decline as its sales will decrease more than $1 billion in 2013, following the entry of generic versions of the drug. By 2019, the drug classes typically used as first-, second-, and third-line therapy will all be subject to generic competition — these drug classes are the angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRA), calcium channel blockers (CCBs) and diuretics.

"Emerging agents will find it difficult to penetrate the highly genericized hypertension market because of competition from inexpensive and efficacious generic antihypertensive drugs," said Decision Resources Analyst Taskin Ahmed. "Through 2019, we do not forecast blockbuster sales for any of the emerging antihypertensive agents."

The Pharmacor 2010 findings also reveal that, although the overall market will decline, sales of therapies offering greater convenience, such as fixed-dose combinations, will increase over the next several years. The CCB/ renin-angiotensin-aldosterone system (RAAS) inhibitor fixed-dose combinations and CCB/RAAS inhibitor/diuretic fixed-dose combinations will capitalize on this opportunity, generating approximately $6 billion in total sales in 2019.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
2. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
3. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
4. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
5. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
7. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
8. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
9. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... emerging field of molecular electronics could take our ... the construction of tiny circuits from molecular components. ... take on the roles currently played by comparatively-bulky ... researchers from five Japanese and Taiwanese universities has ... electronics: a molecule called picene. In a paper ...
(Date:9/16/2014)... 2014 BlueInGreen® , a ... method for delivering dissolved gases into liquids, announced ... as a manufacturer’s representative firm to its sales ... for municipal water and wastewater applications in the ... was founded in 1992 and serves Quebec and ...
(Date:9/16/2014)... Longmeadow, MA (PRWEB) September 16, 2014 ... appointment of Brian Highley as CEO of CIRTEC. ... this exciting point for the Company.” noted Brian Highley. ... operational performance while sustaining strong organic growth over the ... CIRTEC’s growth by continuing to improve and expand the ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 ... initiatives to position themselves for their 89th ... labeling and encoding, Pharma Packaging Solutions is ... hardware and software and new procedures. Establishing ... Good Manufacturing Practices (cGMP), Pharma Packaging Solutions ...
Breaking Biology Technology:The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2
... 10% to $5.8 Billion, and Reported Diluted Earnings per Share Increased 19% to $0.75. ... ... $0.78, - 2007 Full Year Worldwide Net Revenue Increased 10% to $22.4 Billion and ... Before Certain Significant Items, Increased 12% to ...
... Inc., a,biotechnology company focused on the development of ... Petree and George R. Painter,Ph.D. to the Company,s ... founder and member of P2 Partners, LLC, a ... to forming P2,Partners, Mr. Petree held various executive ...
... A/S,(OMX: GEN) announces its financial calendar for 2008 as follows:, EVENT ... ... Annual General Meeting 2008 ... Wednesday, May 28, 2008 first quarter 2008, Publication of the Interim Report for ...
Cached Biology Technology:Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 2Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 3Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 4Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 5Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 6Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 7Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 8Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 9Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 10Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 11Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 12Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 13Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 14Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year 15Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors 2Genmab's Financial Calendar for 2008 2
(Date:9/16/2014)... choices such as buying clothing not made in a ... bringing their own bags when they go shopping? According ... Consumer Research , ethical consumption is motivated by a ... practices into action. , "Advocates of ethical consumerism suggest ... of the products they choose, but unfortunately only a ...
(Date:9/16/2014)... , Sept. 16, 2014 As open enrollment ... important decisions about their 2015 benefits. According to ... solutions business of Aon plc (NYSE: ... a more proactive role in managing their health care ... ever for individuals to understand how they can make ...
(Date:9/15/2014)... a simple, mechanical solution to avoid chromosome sorting ... Science Express. , This natural ... lead to infertility, miscarriage, or congenital conditions. ... problems, but what exactly goes wrong is often ... Trust Center for Cell Biology at the University ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3
... Ore. The impact of hatcheries on salmon is so ... allow fish to survive and prosper in the hatchery environment, ... in a wild environment. These findings, published this week ... show a speed of evolution and natural selection that surprised ...
... NY The Cary Institute of Ecosystem Studies ... the National Science Foundation (NSF) to develop an ... on the Global Lake Ecological Observatory Network (GLEON), ... scientists, technology experts, engineers, and citizens using environmental ...
... and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have ... compounds with antimalarial activity and will provide it to researchers ... Box have confirmed activity against the blood-stage of P. ... and were selected by experienced medicinal chemists from an ...
Cached Biology News:Evolution at warp speed: Hatcheries change salmon genetics after a single generation 2Evolution at warp speed: Hatcheries change salmon genetics after a single generation 3National Science Foundation awards major grant to Cary Institute 2MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost 2
... polystyrene beads for hydrophobic interaction chromatography. They ... organics of molecular weight less than 2,000 ... for the adsorption of nonpolar substances or ... of detergents such as Triton X-100 and ...
... Immunogen : Fusion protein ... 474-970 of human Mi-2 Formulation: ... NaCl, 0.035% sodium azide, containing ... evaluated by immunoblot on Hela ...
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ) ... mM NaCl, 10 mM sodium ... glycerol, pH 7.5. Recognizes the ... kinase 2 (MAPKAPK-2) protein phosphorylated ...
...
Biology Products: